Regeneron finally joins Trump’s drug pricing push while notching landmark approval

Regeneron Agrees to MFN Pricing and Secures Otarmeni Approval

Regeneron has agreed to the Trump administration's Most Favored Nation drug pricing initiative, becoming the last of 17 companies to comply after nearly nine months. This agreement, which includes lowering prices for several drugs and offering Praluent on TrumpRx, coincides with the FDA's approval of Regeneron's gene therapy, Otarmeni, for congenital hearing loss in children. The company also committed to U.S. R&D and manufacturing investments, securing a three-year relief from potential tariffs. Otarmeni, indicated for otoferlin deficiency, will be provided free in the U.S.

• Regeneron's agreement with the Trump administration involves applying Most Favored Nation pricing to several existing drugs and future medicines, as well as offering its cholesterol-lowering drug Praluent on the government's direct-to-consumer platform, TrumpRx. This commitment follows nearly nine months of holding out and makes Regeneron the last of 17 major pharma companies to join the initiative.
• The agreement provides Regeneron with a significant benefit: a three-year exemption from any tariffs and other pricing mandates that the administration might introduce. This relief is a key incentive for the company's compliance, especially given the 100% levy on patented pharmaceutical imports that hit the industry on April 3.
• Simultaneously, the FDA granted approval to Regeneron's gene therapy, Otarmeni, for congenital deafness caused by otoferlin deficiency in pediatric patients. This landmark approval, supported by Phase 1/2 CHORD study data showing clinically meaningful hearing improvements in 11 of 12 patients, marks Regeneron's first gene therapy and the first FDA-approved medicine targeting an underlying cause of deafness.

Otarmeni: A New Era for Otoferlin Deficiency Treatment

The treatment landscape for congenital deafness due to otoferlin deficiency has undergone a transformative shift over the past five years, marked by the emergence of gene therapy as a viable clinical intervention. Multiple international research groups have advanced AAV-OTOF gene therapy from experimental concept to clinical reality, with eight clinical trials now registered across 51 centers in eight countries. Published trial data from institutions including the Eye and ENT Hospital Fudan University demonstrate that AAV-OTOF gene therapy can restore hearing in congenitally deaf children with DFNB9, with some patients achieving normal auditory thresholds. All groups employ a dual vector approach to reconstitute full-length otoferlin, and collectively report varying degrees of hearing improvement following cochlear gene therapy.

Clinical outcomes from published trials reveal substantial therapeutic benefits, with an average gene therapy effect of 52.4-dB improvement from baseline complete deafness. The response is both rapid, with a 0.74-month time constant, and stable over the initial six months of follow-up. Individual outcomes range from restored normal audibility (≤20 dB HL) to severe hearing loss (≥80 dB HL), and notably, improvement is not limited to young children but extends to adolescents and young adults. Comparative studies demonstrate that gene therapy patients show more rapid improvements in auditory and speech performance than cochlear implant patients, with superior performance in speech perception in noisy environments and enhanced neural processing as measured by mismatch negativity latencies.

The safety profile of AAV-OTOF gene therapy has proven favorable across published trials involving 21 DFNB9 patients, with 244 grade I/II adverse events, only 2 grade III adverse events, and no serious adverse events reported. The most common adverse events include increased lymphocyte counts and elevated cholesterol levels, both manageable and transient. This strong safety record, combined with the substantial hearing improvements observed, positions gene therapy as an emerging alternative to cochlear implantation for monogenic forms of congenital deafness, though cochlear implantation remains the standard intervention for severe-to-profound hearing loss of other etiologies.

Addressing Unmet Needs in Otoferlin Deficiency

Current treatment approaches for congenital deafness due to otoferlin deficiency face significant limitations across traditional interventions and emerging therapies. While gene therapy represents a promising breakthrough, substantial challenges remain in optimizing delivery, ensuring consistent outcomes, and integrating these novel approaches into clinical practice.

• Limited traditional therapeutic options - Medicines to treat otoferlin deficiency are lacking, with cochlear implants serving as the primary treatment option for children with this genetic condition

• Gene therapy expression challenges - Achieving physiological and endogenous patterns of otoferlin expression remains difficult with AAV-mediated otoferlin-overexpression gene therapy approaches

• Cochlear implant limitations in auditory neuropathy - While cochlear implants are the treatment of choice for auditory neuropathy, current evidence shows they benefit only patients with endocochlear lesions, not those with cochlear nerve deficiency or central nervous system disorders

• Precision therapy requirements - Due to the complexity of inner ear structure, diverse nature of deafness genes, and variations in transduction efficiency among different inner ear cell types targeted by AAV, precision gene therapy approaches are required for different genetic forms of deafness

• Clinical integration challenges - Identifying potential candidates for otoferlin gene therapy and integrating this therapy into the clinical toolbox remains an important area requiring development

• Access and diagnostic barriers - Expanding both access to genetic testing and understanding of pathogenic variants in understudied populations represents a critical limitation to implementing novel therapies

• Uncertain broader applicability - Whether the early success of otoferlin gene therapy will be replicated in other forms of genetic hearing loss remains an open question for the field

Clinical Efficacy and Safety from the CHORD Study

Recent clinical investigations in congenital deafness due to otoferlin deficiency have demonstrated promising therapeutic outcomes across multiple international trials. The DB-OTO study by Regeneron Pharmaceuticals represents a landmark open-label, single-group, first-in-human registrational trial (NCT05788536) evaluating dual adeno-associated virus 1 gene therapy delivering human OTOF complementary DNA. In this study of 12 children with OTOF variants and profound deafness, intracochlear infusion of 7.2×10 vector genomes per ear achieved the primary efficacy endpoint in 75% of participants (9 of 12), who demonstrated average behavioral pure-tone audiometry thresholds of 70 dB HL or less at week 24. Notably, six participants could hear soft speech without assistive devices, and three achieved average normal hearing sensitivity. Safety analysis revealed 67 adverse events during or after treatment, none of which led to study discontinuation.

The Chinese AAV-OTOF multicenter trial employed the Anc80L65 capsid system in 10 participants aged 1.5 to 23.9 years with autosomal recessive deafness 9 (NCT05901480). This intervention demonstrated substantial auditory improvements, with pure-tone-average hearing levels improving from baseline 106 ± 9 dB to 52 ± 30 dB across all participants. Additional audiometric measures showed comparable improvements: click auditory brainstem response thresholds improved from 101 ± 1 to 48 ± 26 dB, and tone-burst ABR thresholds from 91 ± 4 to 57 ± 19 dB. The therapeutic effect manifested rapidly within one month, with optimal outcomes observed in participants aged 5-8 years. Safety profiling revealed 162 grade I/II adverse events over 6-12 months, with decreased neutrophil percentage being the most frequent occurrence (16 of 162 events).

A comparative cohort study conducted in China between December 2022 and November 2024 directly evaluated OTOF gene therapy against cochlear implantation in 11 gene therapy patients versus 61 cochlear implant patients. Gene therapy recipients demonstrated superior performance in multiple auditory metrics, including significantly better IT-MAIS/MAIS scores at both 6 months (31.0 vs 23.5; P = 0.01) and 12 months (32.0 vs 28.0; P = 0.007). Additionally, gene therapy patients showed enhanced speech perception in noisy environments and improved music perception capabilities when combined with cochlear implantation. Mean auditory brainstem response thresholds in gene therapy patients improved from greater than 95.0 dB nHL to 54.8 dB nHL at 12 months, demonstrating stable hearing recovery with more rapid auditory and speech development compared to cochlear implant recipients.

Regeneron's Dual Play: MFN Compliance Meets Gene Therapy Innovation

Regeneron's recent announcements paint a compelling picture of a pharmaceutical giant navigating complex market dynamics while pushing the boundaries of scientific innovation. The company's decision to comply with the Most Favored Nation (MFN) drug pricing initiative, a move that includes price adjustments for several drugs and offering Praluent on TrumpRx, signals a strategic concession to evolving government and payer pressures. This compliance, while potentially impacting revenue streams for established assets like Praluent, which has faced historical payer barriers and cost-effectiveness scrutiny as a PCSK9 inhibitor, simultaneously secures crucial tariff relief and reinforces a commitment to domestic R&D and manufacturing.

Crucially, this market access maneuver coincides with the landmark FDA approval of Otarmeni, a gene therapy for congenital hearing loss due to otoferlin deficiency. This represents a significant clinical breakthrough, offering the potential for profound hearing improvement, even restoration, in children with this ultra-rare genetic disorder. The commitment to provide Otarmeni free in the U.S. is a bold, patient-centric strategy that could mitigate initial access barriers and differentiate the therapy in the rare disease space. However, this model also introduces questions about its long-term financial sustainability and the precedent it sets for future high-cost, transformative therapies. The successful rollout of such a complex gene therapy will require meticulous operational execution, from patient identification to specialized administration and long-term follow-up, presenting its own set of logistical challenges. Regeneron is clearly balancing the commercial realities of its mature portfolio with the pioneering spirit of its gene therapy pipeline, positioning itself as a leader in both value-driven market engagement and cutting-edge therapeutic development.